Barakah Profits › United States stocks A–Z

Is Protalix BioTherapeutics, Inc. (PLX) halal?

Yes. Protalix BioTherapeutics, Inc. (PLX) passes our halal screen, as of 17 November 2026. It passes every check.

NYSE · Healthcare · Screened 17 November 2026. Its verdict has not changed since our public ledger began on 24 September 2026.

The four checks

Business activityPassFrom the 10-K (2025): The company's revenue is entirely derived from the sale of biopharmaceutical products for rare diseases (Gaucher and Fabry disease) and related license and R&D services, all of which are permissible.
Interest-bearing debtPassTotal debt is 4.0% of market cap (limit 30%).
Cash & interest-bearing securitiesPassCash & securities are 17.5% of market cap (limit 30%).
Non-permissible income (< 5%)PassInterest income is 1.8% of revenue (limit 5%). The annual report shows no other non-permissible revenue.

Verdict history

No changes recorded since 24 September 2026.

See every change across all stocks on the public verdict ledger.

Frequently asked questions

Is Protalix BioTherapeutics, Inc. stock halal?

Yes. Protalix BioTherapeutics, Inc. (PLX) passes our halal screen, as of 17 November 2026. It passes every check.

Why can Protalix BioTherapeutics, Inc.'s halal status change?

Two of the tests compare debt and cash with the company's market value. When the share price moves, those ratios move, so a stock can cross the 30% line without the business changing at all. Its verdict has not changed since our public ledger began on 24 September 2026.

How does Barakah Profits screen stocks?

We use an AAOIFI-style screen: the business itself must be permissible, interest-bearing debt and interest-bearing cash must each be under 30% of market value, and non-permissible income must be under 5% of revenue. It is an automated estimate, not a fatwa.

Check any stock

Free halal check for US, Australian, Malaysian and Singapore stocks.

Check a stock

AAOIFI-style screen by Barakah Profits. Automated estimate, not a fatwa. Always confirm with a qualified scholar before investing. Financial data provided by Twelve Data. This is general information, not financial advice.